Curis Stock Forecast, Price & News

-0.11 (-1.42 %)
(As of 07/29/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume868,263 shs
Average Volume2.80 million shs
Market Capitalization$701.16 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CRIS News and Ratings via Email

Sign-up to receive the latest news and ratings for Curis and its competitors with MarketBeat's FREE daily newsletter.

Curis logo

About Curis

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation that is in Phase Ia/Ib clinical trial in patients with solid tumors. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. The company was incorporated in 2000 and is headquartered in Lexington, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.86 out of 5 stars

Medical Sector

455th out of 2,214 stocks

Biological Products, Except Diagnostic Industry

68th out of 213 stocks

Analyst Opinion: 3.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Curis (NASDAQ:CRIS) Frequently Asked Questions

Is Curis a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Curis in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Curis stock.
View analyst ratings for Curis
or view top-rated stocks.

What stocks does MarketBeat like better than Curis?

Wall Street analysts have given Curis a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Curis wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Curis?

Curis saw a decline in short interest in the month of July. As of July 15th, there was short interest totaling 11,800,000 shares, a decline of 26.3% from the June 30th total of 16,000,000 shares. Based on an average daily trading volume, of 3,720,000 shares, the short-interest ratio is currently 3.2 days. Currently, 13.2% of the company's stock are sold short.
View Curis' Short Interest

When is Curis' next earnings date?

Curis is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Curis

How were Curis' earnings last quarter?

Curis, Inc. (NASDAQ:CRIS) released its quarterly earnings data on Wednesday, May, 12th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.02. The biotechnology company had revenue of $2.19 million for the quarter, compared to the consensus estimate of $2.68 million. Curis had a negative trailing twelve-month return on equity of 62.24% and a negative net margin of 292.06%.
View Curis' earnings history

How has Curis' stock price been impacted by COVID-19?

Curis' stock was trading at $1.09 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CRIS shares have increased by 602.8% and is now trading at $7.66.
View which stocks have been most impacted by COVID-19

When did Curis' stock split? How did Curis' stock split work?

Curis shares reverse split on Wednesday, May 30th 2018. The 1-5 reverse split was announced on Tuesday, May 22nd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 29th 2018. An investor that had 100 shares of Curis stock prior to the reverse split would have 20 shares after the split.

What price target have analysts set for CRIS?

4 brokerages have issued 12 month target prices for Curis' stock. Their forecasts range from $18.00 to $24.00. On average, they anticipate Curis' share price to reach $21.00 in the next year. This suggests a possible upside of 174.2% from the stock's current price.
View analysts' price targets for Curis
or view top-rated stocks among Wall Street analysts.

Who are Curis' key executives?

Curis' management team includes the following people:
  • Mr. James E. Dentzer, Pres, CEO & Director (Age 54, Pay $1.04M)
  • Mr. William E. Steinkrauss, Chief Financial Officer (Age 35, Pay $569.86k)
  • Dr. Robert E. Martell, Head of R&D (Age 58, Pay $639.45k)
  • Mr. Mark W. Noel, VP of Technology Management & Intellectual Property (Age 62)
  • Dr. Reinhard Wilhelm von Roemeling, Sr. VP of Clinical Devel.

Who are some of Curis' key competitors?

What other stocks do shareholders of Curis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD), Celldex Therapeutics (CLDX), Micron Technology (MU), Novavax (NVAX), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Amarin (AMRN), Idera Pharmaceuticals (IDRA), ImmunoGen (IMGN) and OPKO Health (OPK).

What is Curis' stock symbol?

Curis trades on the NASDAQ under the ticker symbol "CRIS."

Who are Curis' major shareholders?

Curis' stock is owned by many different retail and institutional investors. Top institutional investors include Emerald Advisers LLC (2.15%), Focused Wealth Management Inc (0.09%) and Lindbrook Capital LLC (0.01%).
View institutional ownership trends for Curis

Which institutional investors are buying Curis stock?

CRIS stock was bought by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Focused Wealth Management Inc, and Lindbrook Capital LLC.
View insider buying and selling activity for Curis
or or view top insider-buying stocks.

How do I buy shares of Curis?

Shares of CRIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Curis' stock price today?

One share of CRIS stock can currently be purchased for approximately $7.66.

How much money does Curis make?

Curis has a market capitalization of $701.16 million and generates $10.84 million in revenue each year. The biotechnology company earns $-29,910,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.

How many employees does Curis have?

Curis employs 28 workers across the globe.

What is Curis' official website?

The official website for Curis is

Where are Curis' headquarters?

Curis is headquartered at 128 Spring Street Building C - Suite 500, LEXINGTON MA, 02421.

How can I contact Curis?

Curis' mailing address is 128 Spring Street Building C - Suite 500, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 617-503-6500 or via email at [email protected]

This page was last updated on 7/30/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.